Today: 25 January 2026
Subscribe
Browse Category

NASDAQ:CDTX News 7 January 2026 - 9 January 2026

Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

New York, January 9, 2026, 12:09 EST — Regular session Merck & Co Inc shares were up about 0.4% at $111.41 on Friday as investors weighed a report that the drugmaker is in talks to buy cancer biotech Revolution Medicines in a deal valued at $28 billion to $32 billion. Revolution shares jumped nearly 16% in extended trading on Thursday…
9 January 2026
·····
Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

New York, Jan 8, 2026, 13:46 EST — Regular session Merck & Co shares rose 1.5% to $110.20 in afternoon trading on Thursday after Wolfe Research upgraded the drugmaker, outpacing a softer health-care sector. The stock traded as high as $112.08 and as low as $107.94, while AbbVie slid about 3.9% and the S&P 500 ETF was little changed. The…
8 January 2026
······
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

New York, Jan 7, 2026, 18:52 EST — After-hours Merck & Co (MRK.N) shares edged down in after-hours trading on Wednesday after U.S. health officials updated the childhood immunization schedule and moved to a single dose for the human papillomavirus (HPV) vaccine, a change that could pressure demand for Merck’s Gardasil shot. The stock was down about 0.2% at $108.60,…
8 January 2026
·····
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

New York, Jan 7, 2026, 15:40 (EST) — Regular session Merck & Co (MRK.N) shares were down about 0.3% at $108.59 in afternoon trade on Wednesday after the drugmaker said it had completed its cash tender offer for Cidara Therapeutics (CDTX.O) and expected to finish the acquisition through a merger later in the day. The company said the deal will…
7 January 2026
·····

Stock Market Today

  • PAL GROUP Holdings Boosts Year-End Dividend to ¥40, Enhancing Shareholder Value
    January 25, 2026, 9:48 AM EST. PAL GROUP Holdings (TSE:2726) announced a 33% increase in its year-end dividend to ¥40 per share, effective May 27, 2026, reflecting stronger sales and profits for the nine months ended November 2025. The move aims to reinforce the company's commitment to stable, profit-linked shareholder returns amid ongoing governance changes, including adjustments to directors and auditors post board meeting. While the dividend hike partially offsets recent share price weakness, key challenges remain, such as maintaining margins and managing leadership transition. Market analysts highlight a nuanced risk-reward balance, with fair value estimates ranging near ¥2,500, suggesting the stock may still be undervalued by 32% despite governance concerns. Investors are advised to monitor capital allocation and board independence as the company navigates these changes.
Go toTop